Luyan Pharma Co.,Ltd. (SHE:002788)

Luyan Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	20,436	20,398	19,785	19,406	17,508	15,499
Other Revenue	72.73	72.73	60.56	56.58	37.16	36.03
Revenue	20,509	20,471	19,846	19,463	17,545	15,535
Revenue Growth (YoY)	1.83%	3.15%	1.97%	10.93%	12.94%	3.51%
Cost of Revenue	19,002	18,948	18,339	17,950	16,179	14,308
Gross Profit	1,507	1,523	1,506	1,512	1,366	1,227
Selling, General & Admin	791.53	789.17	750.99	731.55	701.2	623.69
Research & Development	5.99	5.85	5.53	4.15	2.97	3.77
Other Operating Expenses	47.37	46.9	42.15	41.59	37.85	37.05
Operating Expenses	837.84	838.39	811.62	809.68	765.63	676.89
Operating Income	668.69	684.26	694.86	702.35	600.39	550.18
Interest Expense	-203.89	-206.68	-222.85	-219.1	-190.28	-163.93
Interest & Investment Income	2.98	3.84	5.14	3.86	5.18	3.47
Currency Exchange Gain (Loss)	-0.95	-0.95	-0.03	0.1	0.01	0.04
Other Non Operating Income (Expenses)	-10.34	-12.08	-6.95	-22.91	-13.14	-13.98
EBT Excluding Unusual Items	456.49	468.38	470.16	464.3	402.15	375.78
Impairment of Goodwill	-	-	-	-	-1.89	-17.5
Gain (Loss) on Sale of Investments	-20.24	-18.73	-12.16	-6.92	-2.14	-2
Gain (Loss) on Sale of Assets	-0.01	0.17	0.28	0.13	-0.53	0.03
Asset Writedown	0.37	-0.09	-0.13	-0.03	-1.7	-1.96
Legal Settlements	-	-	-	-	-	-1.26
Other Unusual Items	3.67	3.53	11.27	8.54	19.33	18.07
Pretax Income	440.28	453.27	469.42	466.01	415.22	371.16
Income Tax Expense	106.35	105.58	104.93	115.04	110.6	104.3
Earnings From Continuing Operations	333.93	347.7	364.49	350.97	304.61	266.86
Minority Interest in Earnings	-0.74	-2.05	-0.96	-5.82	1.26	-0.24
Net Income	333.19	345.64	363.53	345.16	305.87	266.63
Net Income to Common	333.19	345.64	363.53	345.16	305.87	266.63
Net Income Growth	-9.32%	-4.92%	5.32%	12.84%	14.72%	4.20%
Shares Outstanding (Basic)	392	388	387	388	387	360
Shares Outstanding (Diluted)	392	388	387	388	387	360
Shares Change (YoY)	1.39%	0.42%	-0.28%	0.17%	7.46%	9.83%
EPS (Basic)	0.85	0.89	0.94	0.89	0.79	0.74
EPS (Diluted)	0.85	0.89	0.94	0.89	0.79	0.74
EPS Growth	-10.56%	-5.32%	5.62%	12.66%	6.76%	-5.13%
Free Cash Flow	297.74	216.36	779.91	-95.4	-615.51	-110.35
Free Cash Flow Per Share	0.76	0.56	2.02	-0.25	-1.59	-0.31
Dividend Per Share	0.350	0.350	0.300	0.300	0.300	0.200
Dividend Growth	16.67%	16.67%	-	-	50.00%	33.33%
Gross Margin	7.35%	7.44%	7.59%	7.77%	7.79%	7.90%
Operating Margin	3.26%	3.34%	3.50%	3.61%	3.42%	3.54%
Profit Margin	1.63%	1.69%	1.83%	1.77%	1.74%	1.72%
Free Cash Flow Margin	1.45%	1.06%	3.93%	-0.49%	-3.51%	-0.71%
EBITDA	737.22	750.86	753.71	757.8	654.87	598.64
EBITDA Margin	3.60%	3.67%	3.80%	3.89%	3.73%	3.85%
D&A For EBITDA	68.53	66.6	58.85	55.45	54.48	48.46
EBIT	668.69	684.26	694.86	702.35	600.39	550.18
EBIT Margin	3.26%	3.34%	3.50%	3.61%	3.42%	3.54%
Effective Tax Rate	24.15%	23.29%	22.35%	24.69%	26.64%	28.10%
Revenue as Reported	20,509	20,471	19,846	19,463	17,545	15,535
Advertising Expenses	-	4.06	1.27	1.94	1.7	1.47

Source: S&P Global Market Intelligence. Standard template. Financial Sources.